China's top 100 chemical and pharmaceutical industry enterprises revealed that the top three rankings have changed

"Pharmaceutical Network Industry Dynamics" October 13, "2020 China's chemical and pharmaceutical industry outstanding enterprises and outstanding product brands" list was announced, this list is one of the influential brands in the domestic pharmaceutical industry.
On the 2020 China Chemical and Pharmaceutical Industry Industrial Enterprises comprehensive strength of the top 100 list, Yangzijiang Pharmaceuticals, Shanghai Pharmaceuticals, Hengrui Pharmaceuticals ranked in the top three, followed by Fosun Pharma, Zhengda Tianqing and so on.
top 10 companies also include Colum Pharmaceuticals, Qilu Pharmaceuticals, AstraZenecom, Lunan Pharmaceuticals and Howson Pharmaceuticals.
, Yangzijiang Pharmaceuticals has been ranked in the chemical pharmaceutical industry for 6 consecutive years in the comprehensive strength of industrial enterprises in the top 100.
2019, Yangzijiang Pharmaceutical Group achieved sales, profits and taxes increased by 11.94 percent and 16.2 percent year-on-year, respectively, and its overall strength reached new heights.
It is learned that the company has always adhered to the main pharmaceutical industry, adhering to the "high quality, benefit the people, innovation, the best" core values, the implementation of innovation, quality and brand "three-wheel drive" development strategy, a high starting point layout of large health industry, deepen supply-side structural reform, in order to revitalize national medicine, the benefit of human health unremitting progress.
, a large number of famous products, such as Dzosin, blue herring oral liquid, Su Huang cough capsules, to maintain a high market share.
In addition, enterprises pursue the "pharmaceutical for parents, pharmaceutical for relatives" quality culture, "Yangzijiang water feeding China, Yangzijiang medicine for the benefit of Huaxia" brand culture, to achieve the coordinated development of the brand and the market, quality and efficiency of simultaneous improvement.
Shanghai Pharmaceuticals is still ranked second in the top 100, the company adheres to the direction of innovation and development, major diseases and chronic diseases to provide safe and effective treatment drugs as a development focus.
Relying on its fruitful research and development results, Shanghai Pharma's research and development strength has also been highly recognized by the industry, and compared with the previous year's list, Hengrui Pharma than Fosun Pharma advanced a ranking, it can be seen that its research and development strength and innovation results continue to appear.
it's worth noting that the positive weather is rising again compared with the previous year.
is an innovative pharmaceutical group that combines scientific research, production and sales.
decades, the company has always taken research and development innovation as an important strategy for enterprise development, and gradually formed a sound research and development innovation system and competitive advantage.
In recent years, ZhengDaTianQing is committed to building liver disease, tumor, breathing, infection, endocrinology and cardiovascular six major product clusters, in the study of more than 170 products, including a class of more than 30 new drugs, more than 20 biological drugs.
This time Zhengda Tianqing Pharmaceutical Group, "2020 China's chemical pharmaceutical industry industrial enterprises comprehensive strength of the top 100", "2020 China's chemical pharmaceutical industry innovative outstanding corporate brands" two awards, a total of 19 awards, including anti-tumor class of new drugs Androttini won the "2020 China's chemical pharmaceutical industry innovation drug special award."
, an anti-tumor and other innovative drug that has been developed independently for more than ten years and cost more than one billion yuan.
As a new type of small molecule multi-target tyrosine kinase inhibitor, hydrochloric acid arotetini capsule provides an effective new treatment method for the third-line treatment of patients with advanced non-small cell lung cancer in China, and becomes the first approved third-line treatment drug for advanced non-small cell lung cancer in China.
Hydrochloric acid atrotini capsules listed, quickly entered the national 1 category of new drugs, the country's "major new drug creation" science and technology major special support team, but also become the 2018 national anti-cancer drug national health insurance negotiations successfully domestic original research and innovation drugs.
Zhengtianqing won a number of awards this time, but also can be seen in its innovative development achievements.